Form 4: ArriVent BioPharma COO Robin LaChapelle Exercises Stock Options

ArriVent BioPharma, Inc.'s Chief Operating Officer, Robin LaChapelle, reported the exercise of stock options to acquire 11,153 shares of common stock at an exercise price of $2.28 per share.

Summary

• Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, Inc. (AVBP), reported transactions on July 11, 2025.
• Exercised stock options to acquire a total of 11,153 shares of common stock.
• The exercise price for all acquired shares was $2.28 per share.
• Following these transactions, direct beneficial ownership of common stock increased to 135,736 shares.
• An additional 394,477 shares of common stock are indirectly held by The MAKS Yao Trust, for which Robin LaChapelle is the Trustee but disclaims pecuniary interest and beneficial ownership.
• Remaining unexercised stock options include 410 options from a grant that began vesting on September 8, 2022, and 19,243 options (12,873 + 6,370) from a grant that began vesting on February 1, 2023.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates an insider exercising options, which can be seen as a positive action by the individual, but it's a routine compensation event and not indicative of significant new company news.

Positives

• The exercise of stock options indicates a conversion of potential equity into actual shares, potentially reflecting confidence in the company's future.
• The exercise price of $2.28 per share is relatively low, suggesting a favorable acquisition cost for the insider.

Future Outlook

The document indicates future vesting schedules for remaining stock options, with portions vesting in 36 equal monthly installments following initial vesting dates of September 8, 2022, and February 1, 2023, contingent on continued service.

Management Comments

• The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.

Industry Context

This filing represents a routine insider transaction within the biotechnology or pharmaceutical industry, where executive compensation often includes stock options. Such exercises are common and typically reflect an executive's compensation structure rather than broader industry trends.

Related Party Transactions

• Robin LaChapelle is the Trustee of The MAKS Yao Trust, which holds 394,477 shares of common stock. While LaChapelle disclaims pecuniary interest and beneficial ownership, the trust is considered a related party due to the trustee relationship.

Stakeholder Impact

• Shareholders: Minor impact, as it's a routine insider transaction. It could be seen as a slight positive signal if the insider is increasing direct ownership.

Next Steps

• Remaining stock options will continue to vest in 36 equal monthly installments, subject to Robin LaChapelle's continued service.

Key Dates

Keywords

ArriVent BioPharma, AVBP, Robin LaChapelle, Form 4, SEC filing, insider trading, stock options, common stock, beneficial ownership, Chief Operating Officer